09.19.12
Naturex, a France-based manufacturer of natural specialty ingredients has acquired Massachusetts-based Decas Botanical Synergies, which specializes in cranberry extracts and powders for use in nutraceutical tablets, capsules, soft gels, soft chews etc.
Decas Botanical Synergies’ ingredients comprehensive portfolio includes Proanthocyanidin (PAC) standardized powders and extracts, as well as juice concentrate powders and cold pressed seed oils. The flagship brand PACran® is supported by two clinical studies, six US and three international patents. A proprietary blend of the whole fruit, PACran® delivers the entire spectrum of the Cranberry. In addition, PACran® is the first Cranberry ingredient in the World to receive a Health Claim (in Korea), and can be labeled in the US market “PACran® helps support urinary tract health.”
Naturex said Decas Botanical Synergies’portfolio and team of cranberry experts will benefit from its R&D and quality control, while enhancing its innovative products pipeline. The products will be manufactured in Naturex factories, which the company said “will ensure their consistent supply in Europe, Africa, the Americas and Asia through our worldwide sales network. Our aim is to pursue and accelerate the development of this portfolio perfectly in line with consumer demand for healthy, safe and convenient products – and meeting our customer’s needs with innovative and ready-to-use ingredients.”
"We are delighted to welcome the Decas Botanical Synergies team into our Group,” said Thierry Lambert, the Group's vice president and chief executive officer. “This operation allows us to become the leader in Cranberry extracts and is an excellent opportunity to strengthen our position in the development and sales of technical solutions with high-value added offerings for our customers.”
“We are very pleased to join the Naturex Group and we look forward to playing an active role in this new organization,” said Doug Klaiber, CEO of Decas Botanical Synergies. “The expertise of Naturex's scientific teams combined with the strength of its sales network will allow us to accelerate the development of our innovative and clinically substantiated product range, through a differentiating offering."
Decas Botanical Synergies’ ingredients comprehensive portfolio includes Proanthocyanidin (PAC) standardized powders and extracts, as well as juice concentrate powders and cold pressed seed oils. The flagship brand PACran® is supported by two clinical studies, six US and three international patents. A proprietary blend of the whole fruit, PACran® delivers the entire spectrum of the Cranberry. In addition, PACran® is the first Cranberry ingredient in the World to receive a Health Claim (in Korea), and can be labeled in the US market “PACran® helps support urinary tract health.”
Naturex said Decas Botanical Synergies’portfolio and team of cranberry experts will benefit from its R&D and quality control, while enhancing its innovative products pipeline. The products will be manufactured in Naturex factories, which the company said “will ensure their consistent supply in Europe, Africa, the Americas and Asia through our worldwide sales network. Our aim is to pursue and accelerate the development of this portfolio perfectly in line with consumer demand for healthy, safe and convenient products – and meeting our customer’s needs with innovative and ready-to-use ingredients.”
"We are delighted to welcome the Decas Botanical Synergies team into our Group,” said Thierry Lambert, the Group's vice president and chief executive officer. “This operation allows us to become the leader in Cranberry extracts and is an excellent opportunity to strengthen our position in the development and sales of technical solutions with high-value added offerings for our customers.”
“We are very pleased to join the Naturex Group and we look forward to playing an active role in this new organization,” said Doug Klaiber, CEO of Decas Botanical Synergies. “The expertise of Naturex's scientific teams combined with the strength of its sales network will allow us to accelerate the development of our innovative and clinically substantiated product range, through a differentiating offering."
